TK 216

Drug Profile

TK 216

Alternative Names: TK-216

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Tokalas, Inc.
  • Developer Oncternal Therapeutics, Inc.
  • Class Antineoplastics
  • Mechanism of Action Proto-oncogene-protein-c-ets inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Ewing's sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ewing's sarcoma
  • Preclinical Acute myeloid leukaemia; Diffuse large B cell lymphoma; Glioblastoma; Prostate cancer

Most Recent Events

  • 27 Jan 2017 Preclinical trials in Glioblastoma in USA (unspecified route)
  • 27 Jan 2017 Preclinical trials in Prostate cancer in USA (unspecified route)
  • 06 Dec 2016 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top